The Week Ahead: Hom...
Health Care: Drugs
AVANIR Pharmaceuticals (AVNR: NASDAQ)
$3.32 0.02 | 0.61%
05/17/13 - 04:00 PM ET
Company Income Statement
| Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
| Sales | 41.28M | 10.50M | 2.90M | 4.18M |
| Cost of Sales | 1.21M | 8.14K | 197.64K | 83.36K |
| Gross Operating Profit | 40.07M | 10.49M | 2.70M | 4.09M |
| Selling, General, and Administrative Expenses | 74.49M | 55.43M | 16.47M | 10.15M |
| Research & Development | 23.07M | 15.25M | 13.32M | 15.87M |
| Operating Income before D & A (EBITDA) | -57.49M | -60.19M | -27.10M | -21.92M |
| Depreciation & Amortization | 913.06K | 437.84K | 205.00K | 260.78K |
| Interest Income | 42.82K | 38.78K | 15.02K | 204.19K |
| Other Income - Net | 4.08K | -37.73K | 390.76K | -271.82K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -58.36M | -60.63M | -26.90M | -22.25M |
| Interest Expense | 1.39M | 0.00 | 0.00 | 517.00 |
| Pre-Tax Income | -59.74M | -60.63M | -26.90M | -22.25M |
| Income Taxes | 3.20K | 3.20K | 3.20K | 3.20K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -59.74M | -60.63M | -26.69M | -22.00M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -59.74M | -60.63M | -26.69M | -22.00M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -59.74M | -60.63M | -26.69M | -22.00M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-59.74M | -60.63M | -26.69M | -22.00M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -59.74M | -60.63M | -26.69M | -22.00M |
| Basic EPS from Continuing Ops. | -0.45 | -0.51 | -0.30 | -0.28 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.45 | -0.51 | -0.30 | -0.28 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.45 | -0.51 | -0.30 | -0.28 |
| Basic Normalized Net Income/Share | -0.45 | -0.51 | -0.30 | -0.28 |
| EPS fr Continuing Ops. | -0.45 | -0.51 | -0.30 | -0.28 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.45 | -0.51 | -0.30 | -0.28 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.45 | -0.51 | -0.30 | -0.28 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.45 | -0.51 | -0.30 | -0.28 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with AVNR
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Most Shorted Stocks in B...
- Contributor5 Stocks Under-$10 Setting ...
- Contributor5 Biotech Drug-Launch Stock...
- ContributorBreakout Stocks Of The Week...
- UserMy Portfolio
- Contributor6 Heavily Shorted Stocks 04...
Latest AVNR Headlines from TheStreet
- Arena Pharmaceuticals And 6 More Stocks To Watch 01.07.13 | 07:01 pm
- 5 Stocks Facing an Earnings Short Squeeze 12.10.12 | 12:12 pm
- 5 Stocks Under $10 Set to Soar Higher 08.30.12 | 12:08 pm
- Avanir Pharmaceuticals' CEO Presents At Canaccord Genuity 32nd Annual Growth Conference (Transcript) 08.14.12 | 02:08 pm
- Avanir Pharmaceuticals' CEO Discusses F3Q12 Results - Earnings Call Transcript 08.08.12 | 09:08 pm
- Avanir Pharmaceuticals CEO Presents At Bank Of America Merrill Lynch Health Care Conference (Transcript) 05.17.12 | 05:05 pm
- Avanir Pharmaceuticals' Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript) 05.09.12 | 11:05 pm
- Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript 05.08.12 | 03:05 pm
- Avanir's CEO Presents At Citi 2012 Global Health Care Conference - Transcript 02.29.12 | 01:02 pm
- AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript 02.07.12 | 10:02 pm
Press Releases for AVNR
- Avanir Pharmaceuticals Announces Appointment Of Corinne Nevinny To Board Of Directors - PR Newswire 03.11.13 | 04:03 pm
- AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY - PR Newswire 03.06.13 | 09:03 am
- AVANIR Pharmaceuticals To Paticipate In Two Conferences In March - PR Newswire 03.01.13 | 09:03 am
- Avanir Pharmaceuticals To Present At RBC Capital Markets' 2013 Global Healthcare Conference - PR Newswire 02.14.13 | 04:02 pm
- Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786 - PR Newswire 02.07.13 | 08:02 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2013 First Quarter Financial Results And Conference Call - PR Newswire 01.30.13 | 08:01 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Fourth Quarter And Year End Financial Results And Conference Call - PR Newswire 12.03.12 | 08:12 am
- Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update - PR Newswire 11.27.12 | 08:11 am
- Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference - PR Newswire 11.21.12 | 08:11 am
- The Michael J. Fox Foundation Awards Grant To Support Avanir Pharmaceuticals' Clinical Study Of AVP-923 For Levodopa Induced Dyskinesia In Parkinson's Disease - PR Newswire 10.23.12 | 08:10 am
Partner Headlines for AVNR
- Avanir Pharmaceuticals Earnings: Here’s Why Investors Don’t Like These Results - Wall St. Cheat Sheet 05.08.13 | 07:05 am
- Pre-Market Most Active for Apr 26, 2013 : NOK, QQQ, ASML, BAC, MTU, RESI, JCP, BCS, FB, AVNR, ZNGA, SPNC - NASDAQ 04.26.13 | 12:04 pm
- Acorda: A Biotech Company To Consider - Seeking Alpha 04.13.13 | 09:04 am
- After-Hours Earnings Report for December 12, 2012 : AVNR, INTL - NASDAQ 12.12.12 | 07:12 pm
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel ... - GuruFocus 06.30.12 | 11:06 am
- Ultimate Stock Watch List for The Supreme Court's Health Care Ruling - Benzinga 06.28.12 | 09:06 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- Avanir Pharmaceuticals: Limelight On The Horizon - Seeking Alpha 02.17.12 | 06:02 am
- Canaccord Reiterates Buy, $6 PT on Avanir Pharmaceuticals - Benzinga 11.30.11 | 09:11 am
